PMID- 25877941
OWN - NLM
STAT- MEDLINE
DCOM- 20160125
LR  - 20181202
IS  - 2296-5262 (Electronic)
IS  - 2296-5270 (Linking)
VI  - 38
IP  - 4
DP  - 2015
TI  - Treatment of venous thromboembolism in ambulatory cancer patients in Germany: a 
      prospective non-interventional study.
PG  - 174-80
LID - 10.1159/000380871 [doi]
AB  - BACKGROUND: Venous thromboembolism (VTE) is a serious threat for all cancer 
      patients. This study was aimed to assess the VTE treatment of cancer patients in 
      the ambulatory care setting. PATIENTS AND METHODS: This is a prospective 
      non-interventional study, which includes ambulatory cancer patients from 
      office-based oncologists. A standardized case report form was used to obtain data 
      on patient characteristics, treatment regimens, duration of treatment, and side 
      effects. RESULTS: Specialists from 34 centers included data from 76 patients. The 
      median patient age was 62 years (range 33-81 years). The 4 most common cancer 
      types were breast cancer (32%), colorectal cancer (18%), lymphoma and lung cancer 
      (each 8%). 18% of the acute VTE cases were treated as inpatients, 80% as 
      outpatients, and 99% with low-molecular-weight heparin (LMWH), unfractionated 
      heparin (UFH), or fondaparinux. After the acute phase, secondary prophylaxis with 
      LMWH/UFH/fondaparinux was planned in 61% of the patients, with oral 
      anticoagulation in 39%. During acute-phase treatment and secondary prophylaxis, 
      no patient had recurrent VTE. 4 patients (5%) experienced minor bleedings. 
      CONCLUSIONS: This study shows that many ambulatory cancer patients with VTE have 
      early tumors, no metastases, and an excellent performance score. Most patients 
      receive LMWHs for secondary prophylaxis, as recommended by the national and 
      international guidelines. Still, a relevant percentage is switched to oral 
      anticoagulants. (c) 2015 S. Karger GmbH, Freiburg.
FAU - Matzdorff, Axel
AU  - Matzdorff A
AD  - Department of Hematology/Oncology, Caritasklinikum Saarbruecken, Saarbruecken, 
      Germany.
FAU - Schilling, Holger
AU  - Schilling H
FAU - Ledig, Bettina
AU  - Ledig B
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20150304
PL  - Switzerland
TA  - Oncol Res Treat
JT  - Oncology research and treatment
JID - 101627692
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Polysaccharides)
RN  - 9005-49-6 (Heparin)
RN  - J177FOW5JL (Fondaparinux)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Ambulatory Care
MH  - Breast Neoplasms/complications/drug therapy
MH  - Colorectal Neoplasms/complications/drug therapy
MH  - Female
MH  - Fondaparinux
MH  - Germany
MH  - Guideline Adherence
MH  - Heparin/adverse effects/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/adverse effects/*therapeutic use
MH  - Humans
MH  - Lung Neoplasms/complications/drug therapy
MH  - Lymphoma/complications/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*complications/drug therapy
MH  - Polysaccharides/adverse effects/*therapeutic use
MH  - Prospective Studies
MH  - Recurrence
MH  - Surveys and Questionnaires
MH  - Venous Thromboembolism/*drug therapy
EDAT- 2015/04/17 06:00
MHDA- 2016/01/26 06:00
CRDT- 2015/04/17 06:00
PHST- 2015/12/16 00:00 [received]
PHST- 2015/01/28 00:00 [accepted]
PHST- 2015/04/17 06:00 [entrez]
PHST- 2015/04/17 06:00 [pubmed]
PHST- 2016/01/26 06:00 [medline]
AID - 000380871 [pii]
AID - 10.1159/000380871 [doi]
PST - ppublish
SO  - Oncol Res Treat. 2015;38(4):174-80. doi: 10.1159/000380871. Epub 2015 Mar 4.